1. AstraZeneca for early-stage women's cancer drugs.

2. Genentech for novel gynecologic cancer therapies.

• Onapristone extended release (ONA-XR): A progesterone receptor antagonist aimed at overcoming resistance to cancer therapeutics in female hormone-dependent cancers.
• CLDN6xCD3 bsAb: A bispecific monoclonal antibody designed to redirect T-cell-mediated lysis against malignant cells expressing CLDN6.

Context Therapeutics (CNTX) is a clinical-stage biopharmaceutical company focused on developing product candidates for the treatment of cancer. As such, the company is currently engaged in research and development and has not yet brought any products to market for commercial sale. Therefore, Context Therapeutics does not currently have major customers purchasing its products.

Integral Molecular, Inc.

Martin Lehr, Chief Executive Officer

Mr. Lehr is the Co-founder and CEO of Context Therapeutics. He was previously part of the founding team at Osage University Partners, a venture capital fund that invested in technologies from academic universities, focusing on early-stage oncology and rare disease opportunities. Mr. Lehr conducted research at the Sloan Kettering Institute and the Children's Hospital of Philadelphia. He also serves on the Boards of Praesidia Biologics and CureDuchenne Ventures and is a Director of BioBreak.

Jennifer Minai-Azary, Chief Financial Officer

Ms. Minai-Azary was appointed Chief Financial Officer of Context Therapeutics in November 2021.

Karen Chagin, MD, Chief Medical Officer

Dr. Chagin is the Chief Medical Officer of Context Therapeutics. Before joining Context, she served as Senior Vice President of Early-Stage Development at Adaptimmune, where she played a critical role in the development and approval of Tecelra (afamitresgene autoleucel). She also held positions of increasing responsibility, culminating as Chief Medical Officer, at Tmunity from 2019 to 2023.

Alex Levit, Esq, Chief Legal Officer

Mr. Levit was appointed Chief Legal Officer of Context Therapeutics in April 2021.

Christopher Beck, MBA, SVP of Operations

Mr. Beck joined Context Therapeutics in January 2022 as SVP of Operations. He is a pharmaceutical leader with a 30-year career spanning private, public, startup, and high-growth Pharmaceutical and Biotech companies. Previously, Mr. Beck served as Vice President Program Management at Galera Therapeutics.

Context Therapeutics Inc. (CNTX) faces several key risks inherent to its nature as a clinical-stage biopharmaceutical company.

1. Clinical Development and Regulatory Approval Risk: As a company primarily focused on developing novel treatments for cancer, Context Therapeutics' success hinges on the successful outcome of its ongoing clinical trials for product candidates such as CTIM-76, CT-95, and CT-202. There is a significant risk that these product candidates may fail to demonstrate efficacy or sufficient safety profiles during preclinical and clinical testing, or may not receive the necessary regulatory approvals (e.g., from the FDA) required for commercialization. Such failures would materially and adversely affect the company's business, financial condition, and prospects.
2. Funding and Capital Requirements Risk: Context Therapeutics is a clinical-stage company with a limited operating history and no products currently generating revenue from sales. Consequently, the company is highly dependent on raising substantial additional capital to fund its research and development activities, conduct clinical trials, and support its operations through to potential commercialization. While the company has reported a cash runway extending into 2027, it will require significant future financing. An inability to secure this additional funding on favorable terms or at all could force the company to delay, reduce, or terminate its product development programs or other business operations.
3. Limited Operating History and Commercialization Risk: Given its status as a clinical-stage biopharmaceutical company, Context Therapeutics has a limited operating history and has not yet successfully commercialized any products or generated product sales revenue. This makes it challenging to evaluate the company's business and future prospects. Even if product candidates successfully complete clinical trials and obtain regulatory approval, there is no guarantee that the company will be able to successfully commercialize them, achieve market acceptance, build necessary sales and marketing infrastructure, or generate significant sales, all of which are crucial for sustained profitability.

BioNTech's CLDN6 CAR-T program (BNT211) represents a clear emerging threat. While Context Therapeutics is developing a CLDN6xCD3 bispecific antibody to target CLDN6-expressing malignant cells in gynecologic cancers, BioNTech has a CLDN6-targeted CAR-T cell therapy (BNT211) that has shown promising early clinical data in solid tumors, including ovarian cancer and testicular cancer, which fall under the relevant cancer types. CAR-T cell therapy is a distinct and potentially more potent therapeutic modality compared to bispecific antibodies for targeting specific antigens on cancer cells. If BioNTech's CLDN6 CAR-T continues to demonstrate superior efficacy or durability, it could significantly disrupt the market potential for Context Therapeutics' CLDN6 bispecific antibody program by offering a more impactful treatment option for the same patient population and target, akin to a newer, more advanced technology challenging an existing approach.

Context Therapeutics Inc. (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, is focused on developing novel treatments for solid tumors, particularly female cancers. As the company does not currently have commercialized products, analysts forecast zero revenue for 2026 and 2027. However, projections indicate the potential for significant revenue growth beginning in 2028. The primary drivers of future revenue growth for Context Therapeutics over the next 2-3 years are expected to stem from the advancement and potential commercialization of its pipeline of T-cell engaging bispecific antibodies, alongside strategic partnerships.

The key expected drivers of future revenue growth include:

1. Successful Clinical Development and Potential Commercialization of CTIM-76: CTIM-76 is a selective Claudin 6 (CLDN6) x CD3 bispecific antibody being developed for CLDN6-positive tumors. The company initiated a Phase 1 clinical trial for CTIM-76 in January 2025, targeting ovarian, endometrial, and testicular cancers. Initial dose escalation data from this trial are anticipated in the first half of 2026. Positive clinical outcomes and subsequent regulatory approvals would be a significant driver for future revenue.
2. Advancement and Potential Commercialization of CT-95: CT-95 is an avidity-enhanced mesothelin (MSLN) x CD3 bispecific antibody. Context Therapeutics began a Phase 1 clinical trial for CT-95 in April 2025, focusing on patients with mesothelin-expressing cancers, including ovarian, pancreatic, and mesothelioma. Initial clinical data for CT-95 are expected by mid-2026. Favorable trial results leading to further development and eventual market entry would contribute to revenue growth.
3. Progress in Clinical Development of CT-202: CT-202 is a Nectin-4 x CD3 bispecific antibody. The company expects to complete the necessary regulatory filings to initiate a first-in-human trial for CT-202 in the second quarter of 2026. Successful progression of this candidate through clinical trials could also open avenues for future revenue generation.
4. Strategic Partnerships and Licensing Agreements: As a clinical-stage company, Context Therapeutics could generate revenue through collaborations, licensing deals, and milestone payments. Analysts have highlighted the potential for CTIM-76 to attract partnerships due to its unique mechanism. Such agreements could provide upfront payments, research funding, and future royalties on product sales if their pipeline candidates are successfully developed and commercialized by partners.

Share Issuance

• Context Therapeutics expanded its at-the-market (ATM) equity offering program to an aggregate amount of $75 million on October 24, 2025.
• Prior to this amendment, the company had sold approximately $15 million worth of shares under the previous ATM arrangement.
• The net proceeds from these offerings are designated for research and development of product candidates, working capital, general corporate purposes, and potentially for acquiring additional assets.

Outbound Investments

• Context Therapeutics acquired CT-95 in July 2024.
• The company in-licensed CT-202 in September 2024.

Capital Expenditures

• Context Therapeutics reported capital expenditures of approximately -$17.0 thousand in 2025.
• Capital expenditures were approximately -$33,948 over the 12 months leading up to Q3 2025.